MT027 cell injection for advanced peritoneal tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental cell therapy, MT027, for people with advanced peritoneal tumors that have stopped responding to standard treatments. The goal is to see if MT027 can shrink tumors when injected directly into the abdomen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of primary peritoneal cancer or malignant peritoneal mesothelioma, or a secondary peritoneal tumor from stomach, colorectal, ovarian, or fallopian tube cancer.
- You have tried at least one standard treatment (for primary tumors) or two standard treatments (for secondary tumors) that did not work or caused severe side effects.
- You are between 18 and 70 years old.
- You have at least one measurable tumor in your abdomen seen on a CT or MRI scan.
- Your tumor cells test positive for a protein called B7-H3 (this can be from a biopsy or ascites fluid sample).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental intraperitoneal therapy (MT027) for people whose advanced solid tumors have spread to the lining of the belly (peritoneum) and haven't responded to standard treatments. It aims to see if this new approach can help shrink or control the cancer.
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
This trial tests a new drug called SY001, which targets a protein called mesothelin found on some cancer cells. It is designed for people with advanced ovarian or pancreatic cancer who have already tried other treatments and whose tumor tissue has mesothelin.
This trial tests a new drug called MT027 for people with advanced cancer that has spread to the lining around the lungs (pleura) and caused fluid buildup. The drug targets a marker on cancer cells called B7-H3. It may help control the fluid and the cancer.
This trial tests a new type of immune cell therapy made from donor cells that are trained to target two specific proteins found on mesothelioma tumors. The goal is to see if these cells can safely shrink tumors or slow the disease when given directly into the chest or belly area.
This trial uses a test on your tumor tissue to find which chemotherapy drugs work best for you, after standard surgery and heated chemotherapy. It aims to make your treatment more effective by choosing drugs that match your cancer.
Hear when a new Peritoneal Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.